Business, energy, technology, markets and global industry news from Business News Today

UZEDY

PharmaDeviceNews UZEDY
Editorial infographic highlighting Medincell’s second FDA-approved drug, Weltruza, featuring an injectable medicine, FDA approval symbol, U.S. launch map and graphics illustrating clinical evidence, royalty potential and commercial outlook.
Pharma & Biotech

Can Weltruza become Medincell’s next growth driver after Uzedy commercial success?

Medincell gains a second FDA-approved drug as Teva prepares Weltruza's U.S. launch. See the clinical evidence, royalties and commercial outlook.

Read More
Teva Pharmaceutical Industries’ once-monthly TEV-’749 could make long-acting olanzapine more practical if FDA review supports use without the three-hour post-injection monitoring required for existing olanzapine depot therapy. Representative image.
Features & Analysis

Teva saw no PDSS across 3,470 injections. Could TEV-’749 finally make long-acting olanzapine practical?

Teva Pharmaceutical Industries has reported new long-term data for once-monthly subcutaneous TEV-’749 ahead of an expected fourth-quarter FDA decision. Its competitive proposition is not a new antipsychotic mechanism, but an attempt to combine established olanzapine efficacy with long-acting dosing without the post-injection monitoring burden that has constrained the existing olanzapine depot.

Read More